Neurocrine’s experimental drug misses primary goal in schizophrenia trial

(Reuters) – Neurocrine Biosciences said its experimental drug did not achieve the primary goal in a mid-stage trial aimed at improving cognitive function in patients with schizophrenia.

(Reporting by Puyaan Singh;Editing by Mohammed Safi Shamsi)